Ftse Mib
33.778,74
-1,51%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
60.346,77
-5,46%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Celldex Therapeutics Inc (CLDX) Celldex Therapeutics Inc (CLDX) Notizie

Celldex Therapeutics Inc

CLDX
37,42
0,42 (1,14%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:50:49
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/4/202414:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
08/3/202413:00GLOBECelldex Therapeutics to Participate in the Leerink Partners..
05/3/202416:30GLOBECelldex Therapeutics to Present at TD Cowen’s 44th Annual..
05/3/202416:10GLOBECelldex Therapeutics Announces Closing of Public Offering of..
01/3/202422:10EDGAR2Form 8-K - Current report
01/3/202422:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/3/202403:14GLOBECelldex Therapeutics Announces Pricing of Upsized $400..
28/2/202422:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202422:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
26/2/202414:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/2/202413:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
26/2/202413:01EDGAR2Form 8-K - Current report
26/2/202413:01GLOBECelldex Reports Fourth Quarter and Year End 2023 Financial..
24/2/202420:05GLOBECelldex Therapeutics Presents Positive 12 Week Results from..
15/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202422:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:52EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202417:48EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202413:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202415:41EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202416:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202422:01GLOBECelldex to Participate in the Guggenheim Healthcare Talks..
05/2/202414:01GLOBECelldex Announces Upcoming Presentation of Barzolvolimab..
04/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202322:15GLOBECelldex Therapeutics to Present at 6th Annual Evercore ISI..
20/11/202322:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/11/202323:03EDGAR2Form 8-K - Current report
08/11/202323:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/11/202305:15GLOBECelldex Therapeutics Announces Pricing of Public Offering of..
07/11/202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/11/202322:01GLOBECelldex Therapeutics Announces Proposed Public Offering of..
06/11/202315:00EDGAR2Form 8-K - Current report
06/11/202312:30GLOBECelldex Therapeutics Announces Positive Topline Results from..
05/11/202321:00GLOBECelldex Therapeutics Presents Positive Data from Prurigo..
03/11/202321:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202321:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:01EDGAR2Form 8-K - Current report
02/11/202321:01GLOBECelldex Reports Third Quarter 2023 Financial Results and..
26/9/202313:01GLOBECelldex Announces Acceptance of Abstract for Barzolvolimab..
25/9/202314:31GLOBECelldex Therapeutics to Present at Cantor Global Healthcare..
08/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:01EDGAR2Form 8-K - Current report
08/8/202322:01GLOBECelldex Reports Second Quarter 2023 Financial Results and..
11/7/202314:01GLOBECelldex Announces Completion of Enrollment in Phase 2 Study..
06/7/202314:01GLOBECelldex Announces First Patient Dosed in Phase 2 Study of..
10/6/202316:45GLOBECelldex Therapeutics Presents Positive Data from..
08/6/202322:01GLOBECelldex Therapeutics Announces Upcoming Barzolvolimab..
02/6/202314:01GLOBECelldex Therapeutics to Present at Jefferies Healthcare..
31/5/202314:01GLOBECelldex Announces First Patient Dosed in Phase 1 Study of..
15/5/202314:01GLOBECelldex Therapeutics Presents Positive Preclinical Data from..
Apertura: 36,74 Min: 36,35 Max: 38,15
Chiusura: 37,00

La tua Cronologia

NASDAQ
CLDX
Celldex Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network